¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"antigen gain"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
¿µ¹® carcinoembryonic antigen ÇÑ±Û ¾Ï¹è¾ÆÇ׿ø
¼³¸í   
  ¿ø·¡ Å¾ÆÀÇ ÀåÁ¶Á÷¿¡¼­ Á¤»óÀûÀ¸·Î Á¸ÀçÇϴ ¹°Áú·Î Å¾Ʊâ ÀÌÈÄ¿¡´Â Á¸ÀçÇÏÁö ¾Ê´Â ¹°ÁúÀÌ´Ù. ±×·¯³ª À§, °£, ÇãÆÄ µîÀÇ ¾ÏÀÌ Àִ °æ¿ì¿¡ ¼ºÀο¡¼­µµ Á¸ÀçÇÑ´Ù. À̸¦ ÀÌ¿ëÇØ¼­ ¾ÏÀÇ Ä¡·áÈ¿°ú ÆÇÁ¤À̳ª Àç¹ß¿©ºÎÀÇ Á¶»ç¿¡ ÀÌ¿ëÇÑ´Ù.
¿µ¹® antigen ÇÑ±Û Ç׿ø
¼³¸í   
  Æ¯ÀÌÇÑ ¸é¿ª¹ÝÀÀÀ» ÀÏÀ¸Å³ ¼ö Àִ ¾î¶°ÇÑ ¹°Áú. ¿©±â¿¡¼­ ¸»Çϴ ƯÀÌÇÑ ¸é¿ª¹ÝÀÀÀ̶õ ºñƯÀÌÀûÀΠ¸é¿ª¹ÝÀÀ°ú´Â ¹Ý´ëµÇ´Â Àǹ̷Π±× ¹°Áú¿¡ ´ëÇØ¼­ Æ¯ÀÌÇϰԠ¹ÝÀÀÇÒ ¼ö Àִ Ç×ü³ª ±× ¹°Áú¿¡ ´ëÇØ¼­ Æ¯ÀÌÇϰԠ¹ÝÀÀÇÒ ¼ö Àִ ¼¼Æ÷¸¦ ¸¸µå´Â °ÍÀ» ¸»ÇÑ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • acoustic gain
    À½ÇâÁõÆø
  • gain
    1. ȹµæ, À̵æ 2. Áõ°¡ 3. ÁõÆø
  • oxygen gain factor
    »ê¼ÒÀ̵æ°è¼ö
  • weight gain
    üÁßÁõ°¡
  • antigen
    Ç׿ø
  • antigen analysis
    Ç׿øºÐ¼®
  • antigen binding capacity
    Ç׿ø°áÇÕ´É
  • antigen binding fragment
    Ç׿ø°áÇÕºÎÀ§
  • antigen binding receptor
    Ç׿ø°áÇÕ¼ö¿ëü
  • antigen capture assay
    Ç׿øÆ÷È¹ÃøÁ¤
  • antigen competition
    Ç׿ø°æÀï
  • antigen diffusion constant
    Ç׿øÈ®»ê»ó¼ö
  • antigen excess
    Ç׿ø°úÀ×
  • antigen excess zone
    Ç׿ø°úÀ×±¸¿ª
  • antigen mimicry
    Ç׿øÀ¯»ç¼º
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • gain
    ȹµæ, À̵æ, Áõ°¡, ÁõÆø
  • antigen
    Ç׿ø
  • antigen analysis
    Ç׿øºÐ¼®
  • carcinoembryonic antigen
    ¾ÏÁ¾¹è¾ÆÇ׿ø
  • platelet-specific antigen
    Ç÷¼ÒÆÇƯÀÌÇ׿ø
  • recombinant antigen
    ÀçÁ¶ÇÕÇ׿ø
  • sequestered antigen
    °Ý¸®Ç׿ø
  • somatic antigen
    ü¼¼Æ÷Ç׿ø, ±ÕüÇ׿ø
  • surface antigen
    Ç¥¸éÇ׿ø
  • tumor antigen
    Á¾¾çÇ׿ø
  • antigen excess
    Ç׿ø°úÀ×
  • antigen presentation
    Ç׿øÀü´Þ
  • antigen receptor
    Ç׿ø¼ö¿ëü
  • antigen-antibody reaction
    Ç׿øÇ×ü¹ÝÀÀ
  • antigen-binding site
    Ç׿ø°áÇÕºÎÀ§
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • acoustic gain
    À½ÇâÁõÆø
  • oxygen gain factor
    »ê¼ÒÀ̵æ°è¼ö
  • therapeutic gain factor
    Ä¡·áÀ̵æ°è¼ö
  • gain
    ȹµæ, À̵æ, Áõ°¡, ÁõÆø
  • weight gain
    üÁßÁõ°¡
  • antigen
    Ç׿ø
  • accessible antigen
    Á¢±Ù°¡´ÉÇ׿ø
  • antigen competition
    Ç׿ø°æÀï
  • antigen excess
    Ç׿ø°úÀ×
  • antigen mimicry
    Ç׿øÀ¯»ç¼º
  • antigen modification
    Ç׿øº¯È­, Ç׿ø¼ö½Ä
  • antigen presentation
    Ç׿øÀü´Þ
  • antigen receptor
    Ç׿ø¼ö¿ëü
  • antigen recognition
    Ç׿øÀÎÁö
  • antigen analysis
    Ç׿øºÐ¼®
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • AGC (automatic gain control)
    ÀÚµ¿ °ÔÀÎ Á¶Àý
  • AGC (automatic gain control)
    ÀÚµ¿ (í»ÔÑ) °ÔÀÎ Á¶Àý (ðàï½), À̵æÀÚµ¿Á¶Àý
  • T.G.C (time gain compensation)
    ½Ã°£ (ãÁÊà) °ÔÀÎ º¸»ó (ÜÍßÁ), °Å¸®(±íÀÌ) °ÔÀÎ º¸»ó
  • T.G.C (time gain compensation)
    ½Ã°£ °ÔÀÎ º¸»ó
  • acoustic gain
    À½Çâ ÁõÆø
  • gain
    °ÔÀÎ
  • primary gain
    ÀÏÂ÷(Àû) À̵æ(ìéó­îÜì¦Ôð).
  • ABH antigen
    ABH Ç׿ø
  • B antigen
    B Ç׿ø(ù÷ê«)
  • B cell antigen
    B ¼¼Æ÷Ç׿ø
  • CA 19-9 antigen
    CA 19-9 Ç׿ø
  • CA 50 antigen
    CA 50 Ç׿ø
  • CA-2<>
    CA-2<<ÄÝ·ÎÀ̵åÇ׿ø>>
  • CD5 antigen
    CD5 Ç׿ø
  • CEA(carcinoembryonic antigen)
    žƼº¾ÏÇ׿ø
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • capsular antigen =K. antigen
    Çù¸·Ç׿ø(¡­ù÷ê«).
  • acoustic gain
    À½Çâ ÁõÆø
  • depth gain compensation
    ±íÀÌ °ÔÀÎ(°­µµ) º¸»ó
  • far gain
    ¿ø°Å¸® °ÔÀÎ
  • far gain
    ¿ø°Å¸® (êÀËå×î) °ÔÀÎ
  • gain
    °ÔÀÎ
  • near gain
    ±Ù°Å¸® °ÔÀÎ
  • near gain
    ±Ù°Å¸® (ÐÎËå×î) °ÔÀÎ
  • oxygen gain factor (OGF)
    »ê¼ÒÀ̵æ°è¼ö
  • primary gain
    ÀÏÂ÷(Àû) À̵æ(ìéó­îÜì¦Ôð).
  • secondary gain
    ÀÌÂ÷¼º À̵æ
  • secondary gain
    ÀÌÂ÷(Àû) À̵æ(¡­ì¦Ôð).
  • therapeutic gain factor, TGF
    Ä¡·áÀ̵æ°è¼ö
  • time gain compensation
    ½Ã°£ (ãÁÊà) °ÔÀÎ º¸»ó (ÜÍßÁ)
  • time gain compensation
    ½Ã°£ °ÔÀÎ º¸»ó
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • circumsporozoite antigen
    Æ÷ÀÚ¼ÒüÇ׿ø
  • egg antigen
    Ãæ¶õÇ׿ø
  • excretory-secretory antigen
    ºÐºñ¹è¼³Ç׿ø
  • metabolic antigen
    ´ë»çÇ׿ø
  • somatic antigen
    üÇ׿ø
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • antigenic gain
    Ç׿ø¼º Áõ°¡(ù÷ê«àõñòÊ¥)
  • GaIN
    (å²) galactosamine
  • antigen
    Ç׿ø(ù÷ê«)
  • antigen binding capacity
    Ç׿ø °áÇÕ´É(ù÷ê«Ì¿ùêÒö)
  • antigen binding site
    Ç׿ø°áÇÕ(ù÷ê«Ì¿ùê)ÀÚ¸®
  • antigen presenting cell
    Ç׿øº¸À¯¼¼Æ÷(ù÷ê«ÜÁêóá¬øà)
  • antigen-antibody complex
    Ç׿øÇ×ü º¹ÇÕü(ù÷ê«ù÷ô÷ ÜÜùêô÷)
  • antigen-antibody lattice
    Ç׿øÇ×ü °ÝÀÚ(ù÷ê«ù÷ô÷ Ì«í­)
  • antigen-antibody reaction
    Ç׿øÇ×ü ¹ÝÀÀ(ù÷ê«ù÷ô÷Úãëë)
  • antigen-binding fragment
    Ç׿ø°áÇÕ(ù÷ê«Ì¿ùê) Á¶°¢
  • antigen-excess zone
    Ç׿ø°úÀ× ±¸¿ª(ù÷ê«Î¦í¥Ï¡æ´)
  • Australia antigen
    ¿À½ºÆ®¶ö¸®¾Æ Ç׿ø (ù÷ê«)
  • Boivin antigen
    º¸¿Í¹æ Ç׿ø(ù÷ê«)
  • complete antigen
    ¿ÏÀüÇ׿ø(èÇîïù÷ê«)
  • conjugated antigen
    Æ÷ÇÕÇ׿ø(øÙùêù÷ê«)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • antigen
    Ç׿ø
  • antigen antibody reaction
    Ç׿øÇ×ü¹ÝÀÀ
  • HLA antigen
    HLAÇ׿ø
  • HLA[=human leukocyte antigen]
    HLAÇ׿ø, Àΰ£¹éÇ÷±¸Ç׿ø
  • homologous antigen
    »óµ¿Ç׿ø
  • AGC [=automatic gain control]
    ÀÚµ¿°ÔÀÎÁ¶Àý
  • depth gain compensation
    ±íÀ̰ÔÀÎ(°­µµ)º¸»ó
  • far gain
    ¿ø°Å¸®°ÔÀÎ
  • gain
    °ÔÀÎ
  • near gain
    ±Ù°Å¸®°ÔÀÎ
  • T.G.C [=time gain compensation]
    ½Ã°£°ÔÀκ¸»ó
  • time gain compensation [=T.G.C.]
    ½Ã°£°ÔÀκ¸»ó
  • time gain compenstaion curve
    ½Ã°£°ÔÀκ¸»ó°î¼±
  • time gain control
    ½Ã°£°ÔÀÎÁ¶Àý
  • total gain
    ÃѰÔÀÎ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
HLA histocompatibility leukocyte antigen; histocompatibility locus antigen; homologous leukocyte antibod...
AGC Automatic Gain Control
AGC absolute granulocyte count; automatic gain control
GaIN Georgia Interactive Network for Medical Information
MGR modified gain ratio; multiple gas rebreathing
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
AGC Automatic Gain Control
ADG Average daily gain
BWG Body weight gain
G Gain
gf Gain-of-function
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • near gain
    ±Ù°Å¸® °ÔÀÎ
  • organ gain access
    ±âÁú À̵æ Á¢±Ù
  • primary gain
    ÀÏÂ÷ À̵æ
  • secondary gain
    ÀÌÂ÷ À̵æ
    °£Á¢ÀûÀÎ À̵æÀ¸·Î¼­ º¸Åë Áúº´À̳ª ¼è¾àÀ¸·ÎºÎÅÍ ¾ò¾îÁø´Ù. À̰ÍÀº Àڽſ¡°Ô ÇØ·Î¿î Àǹ«³ª Ȱµ¿À» ÇÇÇϰí Åë»óÀûÀ¸·Î´Â µµ¿ÍÁÖÁö ¾Ê´Â »ç¶÷À¸·ÎºÎÅÍ ÁöÁö¸¦ ¹ÞÀ» ¼ö ÀÖµµ·Ï ÇÑ´Ù.
  • time gain compensation
    ½Ã°£ °ÔÀÎ º¸»ó
  • time gain control
    ½Ã°£ °ÔÀÎ Á¶Àý
  • weight gain
    üÁß Áõ°¡
    °ú´ÙÇÑ À½½ÄÀÇ ¼·Ãë, ¿îµ¿À¸·Î ÀÎÇÑ ±ÙÀ°ÀÇ Áõ°¡, º´Àû »óȲ µîÀÇ ¿øÀÎÀÌ ÀÖÀ¸³ª º¸Åë °ú½ÄÀ¸·Î ÀÎÇÑ Ã¼Áö¹æÀÇ Áõ°¡ ¶Ç´Â º´À¸·Î ÀÎÇÑ Ã¼ÁßÁõ°¡ µîÀÇ ¶æÀ¸·Î ³ª»Ú°Ô ¾²ÀδÙ.
  • accessible antigen
    Á¢±Ù °¡´É Ç׿ø, ±ÙÁ¢ Ç׿ø
  • antigen adjuvant
    Ç׿ø ¾ÆÁê¹ÝÆ®, Ç׿ø º¸°­Á¦
  • antigen antibody complex
    Ç׿ø Ç×ü º¹ÇÕü
    Ç׿ø°ú Ç×ü°¡ °áÇÕÇÑ °Í. ¸é¿ª º¹ÇÕü¶ó°íµµ ÇÑ´Ù. Ç×ü´Â Ç׿ø°ú °áÇÕÇÏ¿© º¹ÇÕü¸¦ ¸¸µé¸é º¸Ã¼ Ȱ¼ºÈ­ ÀÛ¿ëÀ» °¡Áö°Ô µÈ´Ù. ±×·¡¼­ »ýü ³»¿¡¼­ ¸é¿ª º¹ÇÕü°¡ Çü¼ºµÇ¸é ±× ÁÖº¯¿¡¼­ ºÎü°¡ Ȱ¼ºÈ­µÇ¾î ¿°Áõ¹ÝÀÀÀ» ¹ß»ý½ÃŰ´Â ¼ÀÀÌ´Ù. Ç׿ø Ç×ü º¹ÇÕü´Â ħ°­¼ºÀÇ °ÍÀ¸·Î µÇ±â ½±´Ù. µû¶ó¼­ Ç׿øÀÇ Ä§ÀÔ ºÎÀ§¿¡ ¿°Áõ¹ÝÀÀÀÌ »ý±â±â ½±´Ù.
  • antigen antibody reaction
    Ç׿ø Ç×ü ¹ÝÀÀ
  • antigen binding cell
    Ç׿ø °áÇÕ ¼¼Æ÷
    Ç׿ø¿¡ ´ëÇÑ Æ¯ÀÌÀûÀÎ °áÇձ⸦ ¼¼Æ÷ Ç¥¸é¿¡ °¡Áö°í ÀÖÀ¸¸ç Ç׿øÀ» ¼¼Æ÷ Ç¥¸é¿¡ °áÇÕ½ÃŰ´Â ´É·ÂÀ» °¡Áø ¼¼Æ÷. B ¼¼Æ÷ ¹× ÀϺÎÀÇ T ¼¼Æ÷°¡ Ç׿ø °áÇÕ ¼¼Æ÷¿¡ ÇØ´çµÈ´Ù. À̵éÀÇ ¸²ÇÁ±¸ÀÇ ¼¼Æ÷ Ç¥¸é¿¡ Ç׿øÀÌ °áÇյǾî ÀÖ´Â »óŸ¦ °¢Á¾ ¹æ¹ýÀ¸·Î È®ÀÎÇÒ ¼ö ÀÖ´Ù. Ç׿øÀ» ¹æ»ç¼º ¹°Áú·Î Ç¥ÁöÇØ µÎ°í autoradiogra
  • antigen binding fragment
    Ç׿ø °áÇÕ ºÎÀ§
  • antigen binding site
    Ç׿ø °áÇÕ ºÎÀ§
    ¸é¿ª ±Û·ÎºÒ¸°ÀÇ 3Â÷ ±¸Á¶»ó H ¼â¿Í L ¼âÀÇ °¡º¯¿µ¿ª¿¡¼­ ±¸¼ºµÇ¾î ÀÖ´Â Ç׿ø°ú °áÇÕÇÏ´Â ºÎÀ§.
  • antigen combining site
    Ç׿ø °áÇÕºÎ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
gain <physics> (Amplification) Increase in a signal transmitted from one point to another through an amplifier.
(09 Oct 1997)
weight gain Increase in body weight over existing weight.
(12 Dec 1998)
primary gain Interpersonal, social, or financial advantages from the conversion of emotional stress directly into demonstrably organic illnesses (e.g., hysterical blindness or paralysis).
Compare: secondary gain.
(05 Mar 2000)
secondary gain Interpersonal or social advantages (e.g., assistance, attention, sympathy) gained indirectly from organic illness.
Compare: primary gain.
(05 Mar 2000)
time-compensated gain In ultrasonography, an increase in receiver gain with time to compensate for loss in echo amplitude with depth, usually due to attenuation.
Synonym: attenuation compensation, depth compensation, time compensation gain, time-compensated gain, time-varied gain control, time-varied gain.
(05 Mar 2000)
time compensation gain In ultrasonography, an increase in receiver gain with time to compensate for loss in echo amplitude with depth, usually due to attenuation.
Synonym: attenuation compensation, depth compensation, time compensation gain, time-compensated gain, time-varied gain control, time-varied gain.
(05 Mar 2000)
time-gain compensation In ultrasonography, an increase in receiver gain with time to compensate for loss in echo amplitude with depth, usually due to attenuation.
Synonym: attenuation compensation, depth compensation, time compensation gain, time-compensated gain, time-varied gain control, time-varied gain.
(05 Mar 2000)
time-varied gain In ultrasonography, an increase in receiver gain with time to compensate for loss in echo amplitude with depth, usually due to attenuation.
Synonym: attenuation compensation, depth compensation, time compensation gain, time-compensated gain, time-varied gain control, time-varied gain.
(05 Mar 2000)
time-varied gain control In ultrasonography, an increase in receiver gain with time to compensate for loss in echo amplitude with depth, usually due to attenuation.
Synonym: attenuation compensation, depth compensation, time compensation gain, time-compensated gain, time-varied gain control, time-varied gain.
(05 Mar 2000)
acetone-insoluble antigen A diphosphatidyl glycerol that is found in the membrane of Treponema pallidum and is the antigen detected by the Wasserman test for syphilis.
(18 Nov 1997)
allogeneic antigen Genetic variations of the same antigens within a given species.
(05 Mar 2000)
antigen Virus coded cell surface antigens that appear soon after the infection of a cell by virus, but before virus replication has begun.
See: early gene.
(18 Nov 1997)
antigen-antibody complex The complex formed by the binding of antigen and antibody molecules. The deposition of large antigen-antibody complexes leading to tissue damage causes immune complex diseases. If the antigen is polyvalent the complex may be insoluble.
Immune complexes activate complement through the classical pathway.
See: glomerulonephritis, Arthus reaction, type III hypersensitivity.
(12 Dec 1998)
antigen-antibody reaction The phenomenon, occurring in vitro or in vivo, of antibody combining with antigen of the type that stimulated the formation of the antibody, thereby resulting in agglutination, precipitation, complement fixation, greater susceptibility to ingestion and destruction by phagocytes, or neutralization of exotoxin.
See: skin test.
(05 Mar 2000)
antigen-binding site <immunology> In immune network theory, an idiotope, an antigenic site of an antibody that is responsible for that antibody binding to an antigenic determinant (epitope).
Also used of the site on a ligand molecule to which a cell surface receptor binds.
(18 Nov 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • HY antigen
    H-YÇ׿ø(Y¿°»öü À¯ÀüÀÚ¿¡ ÀÇÁ¸ÇÏ´Â Á¶Á÷ ÀûÇÕ Ç׿ø)
  • Rhesus factor(antigen)
    =RH FACTOR
  • antigen
    Ç׿ø(Ç÷¾×Áß¿¡ antibodyÀÇ Çü¼ºÀ» ÃËÁøÇÏ´Â ¹°Áú)
  • histiocompatibility antigen
    Á¶Á÷ ÀûÇÕ¼º Ç׿ø
  • gain
    ¾ò´Ù,ȹµæÇÏ´Ù,-¿¡ µµ´ÞÇÏ´Ù
  • gain on
    -À» ´É°¡ÇÏ´Ù
  • capital gain
    ÀÚº» ÀÌÀÍ;°íÁ¤ ÀÚ»ê ¸Å°¢¼Òµæ
  • gain
    ÀÌÀÍ;Áõ°¡;Áøº¸;(pl) À̵æ;¹úÀÌ
  • gain
    ÀÌÀÍÀ» ¾ò´Ù;³ª¾Æ°¡´Ù;ÀߵǴÙ;~ (up)on ~¿¡ Á¢±ÙÇÏ´Ù;(¾Æ¹«¿¡°Ô) ºô ºÙ´Ù;~¿¡ ħ½ÄÇÏ´Ù;~ over ¼³º¹½ÃŰ´Ù;(ÀÚ±â ÆíÀ¸·Î)²ø¾îµéÀÌ´Ù
  • gain
    ¾ò´Ù;À̱â´Ù;ȹµæÇÏ´Ù;(¹«°Ô,Èû µîÀÌ)´Ã´Ù;(½Ã°è°¡)´õ °¡´Ù
  • gain control
    (ÀüÀÚ)(¼ö½Å±â,Á߯ø±âÀÇ)À̵æ Á¦¾î
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á